WASHINGTON, Oct. 3, 2018 /PRNewswire/ -- The
Antimicrobials Working Group (AWG), a coalition of companies with
the mission to combat drug resistant infections and spur
life-saving innovations, announced today that 16 of its member
companies will present data from their clinical and research
programs at IDWeek 2018 to be held October
3-7 in San Francisco. AWG
members are presenting a total of 40 poster presentations, four
oral abstract presentations and four features within the symposium
entitled "Exploring the Antibiotic Pipeline 2018."
IDWeek is an annual scientific meeting that brings together
infectious disease professionals to present and discuss the latest
approaches in prevention, diagnosis, treatment, and epidemiology of
infectious diseases.
"We are pleased to have a record number of AWG member companies
presenting at IDWeek this year," said Jeffrey Stein, Ph.D., president and chief
executive officer of Cidara Therapeutics and Chairman of the AWG.
"AWG members look forward to presenting data on new antimicrobial
molecules in development, including findings that explore the role
of novel therapies against antibiotic-resistant organisms, as well
as topics in rapid diagnostics. IDWeek provides a rich opportunity
to engage with infectious disease professionals from various
backgrounds about novel agents, clinical trials, PK/PD studies and
a host of different infections with the common goal of improvement
of patient care and public health."
The following AWG member companies will be presenting at IDWeek
2018: Amplyx Pharmaceuticals, Arsanis Inc. (NASDAQ: ASNS),
Cidara Therapeutics, Inc. (NASDAQ:CDTX), ContraFect Corporation
(NASDAQ:CFRX), Entasis Therapeutics, Iterum Therapeutics plc
(NASDAQ:ITRM), Melinta Therapeutics, Inc. (NASDAQ:MLNT), Motif Bio
plc (AIM/NASDAQ:MTFB), Nabriva Therapeutics Plc (NASDAQ:NBRV),
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), SCYNEXIS, Inc.
(NASDAQ: SCYX), Spero Therapeutics, Inc. (NASDAQ:SPRO), Summit
Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), T2 Biosystems, Inc.
(NASDAQ:TTOO), Theravance Biopharma, Inc. (NASDAQ:TBPH) and
Viamet.
For more information on AWG member company presentations and
access to specific abstracts, please visit:
https://www.antimicrobialsworkinggroup.org/idweek-2018/.
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of nineteen antimicrobials and diagnostics companies:
Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc.,
Cidara Therapeutics Inc., ContraFect Corporation, Entasis
Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics
Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek
Pharmaceuticals Inc., SCYNEXIS Inc., Spero Therapeutics, Inc.,
Summit Therapeutics plc, T2 Biosystems Inc., Theravance Biopharma
U.S. Inc., Viamet, Vical Incorporated, and Zavante Therapeutics
Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-idweek-2018-300723021.html
SOURCE Antimicrobials Working Group (AWG)